Search research articles
Contact Us
Filters
Showing results (71-80 of 188) with videos related to
Page
of 19
Sort By:
Expert Opinion on Pharmacotherapy
|
November 21, 2009
Reduction of blood pressure in patients with treatment-resistant hypertension
Maria Czarina Acelajado, David A Calhoun, Suzanne Oparil
Current Hypertension Reports
|
May 11, 2002
Resistant hypertension
David A Calhoun, Mohammad A Zaman, Mari K Nishizaka
Seminars in Nephrology
|
November 23, 2014
Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels
Eric K Judd, David A Calhoun, David G Warnock
American Journal of Hypertension
|
June 24, 2016
Do We Need a New Definition of Hypertension After SPRINT?
Ernesto L Schiffrin, David A Calhoun, John M Flack
American Journal of Hypertension
|
November 9, 2018
Resistant Hypertension: An Update
David A Calhoun, Ernesto L Schiffrin, John M Flack
American Journal of Hypertension
|
October 24, 2003
Efficacy of low-dose spironolactone in subjects with resistant hypertension
Mari Konishi Nishizaka, Mohammad Amin Zaman, David A Calhoun
Hypertension (Dallas, Tex. : 1979)
|
April 20, 2016
Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure
Tanja Dudenbostel, Mohammed Siddiqui, Suzanne Oparil, et al.
Journal of Nature and Science
|
October 17, 2017
Refractory versus resistant hypertension: Novel distinctive phenotypes
Tanja Dudenbostel, Mohammed Siddiqui, Nitin Gharpure, et al.
American Journal of Hypertension
|
November 25, 2015
SPRINT Proves that Lower Is Better for Nondiabetic High-Risk Patients, but at a Price
Ernesto L Schiffrin, David A Calhoun, John M Flack
Current Hypertension Reports
|
May 26, 2005
Aldosterone antagonism: an emerging strategy for effective blood pressure lowering
Monique N Pratt-Ubunama, Mari K Nishizaka, David A Calhoun
Page
of 19
Search research articles
Search
Showing results (71-80 of 188) with videos related to
Sort By:
Page
of 19
Expert Opinion on Pharmacotherapy
|
November 21, 2009
Reduction of blood pressure in patients with treatment-resistant hypertension
Maria Czarina Acelajado, David A Calhoun, Suzanne Oparil
Current Hypertension Reports
|
May 11, 2002
Resistant hypertension
David A Calhoun, Mohammad A Zaman, Mari K Nishizaka
Seminars in Nephrology
|
November 23, 2014
Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels
Eric K Judd, David A Calhoun, David G Warnock
American Journal of Hypertension
|
June 24, 2016
Do We Need a New Definition of Hypertension After SPRINT?
Ernesto L Schiffrin, David A Calhoun, John M Flack
American Journal of Hypertension
|
November 9, 2018
Resistant Hypertension: An Update
David A Calhoun, Ernesto L Schiffrin, John M Flack
American Journal of Hypertension
|
October 24, 2003
Efficacy of low-dose spironolactone in subjects with resistant hypertension
Mari Konishi Nishizaka, Mohammad Amin Zaman, David A Calhoun
Hypertension (Dallas, Tex. : 1979)
|
April 20, 2016
Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure
Tanja Dudenbostel, Mohammed Siddiqui, Suzanne Oparil, et al.
Journal of Nature and Science
|
October 17, 2017
Refractory versus resistant hypertension: Novel distinctive phenotypes
Tanja Dudenbostel, Mohammed Siddiqui, Nitin Gharpure, et al.
American Journal of Hypertension
|
November 25, 2015
SPRINT Proves that Lower Is Better for Nondiabetic High-Risk Patients, but at a Price
Ernesto L Schiffrin, David A Calhoun, John M Flack
Current Hypertension Reports
|
May 26, 2005
Aldosterone antagonism: an emerging strategy for effective blood pressure lowering
Monique N Pratt-Ubunama, Mari K Nishizaka, David A Calhoun
Page
of 19